Corcept (CORT) Rule 144 Notice: 20,000 Shares From Option Exercise to Be Sold

Rhea-AI Filing Summary

Corcept Therapeutics (CORT) insider filing under Rule 144 reports a proposed sale of 20,000 common shares through Stifel Nicolaus & Co., with an aggregate market value of $1,662,200 and an approximate sale date of 10/01/2025. The filing states the 20,000 shares were acquired via a stock option exercise and paid in cash on 10/01/2025. The filer also disclosed multiple prior open-market sales by the same person over the past three months totaling 62,000 shares with gross proceeds reported for each trade. The notice includes the required representation that the seller is not aware of undisclosed material adverse information.

Positive

• Full compliance with Rule 144 disclosure requirements showing acquisition method, payment, and planned sale channel
• Transparency on recent insider sales with a detailed list of trades and gross proceeds over the past three months

Negative

• Insider selling activity is material: 20,000-share proposed sale valued at $1,662,200 could be seen as liquidity-taking by an insider
• Significant prior dispositions: 62,000 shares sold in the prior three months, which may concern some investors monitoring insider selling trends

Insights

Securities Analyst

TL;DR: Insider is selling a material block of 20,000 shares and has sold 62,000 shares in the past three months; transaction is disclosed under Rule 144.

The filing documents a Rule 144 notice for a 20,000-share sale valued at $1,662,200 executed through Stifel Nicolaus with an approximate sale date of October 1, 2025. The shares were acquired by exercise of stock options and paid in cash on the same date. Recent historical dispositions by the same holder show patterned monetization totaling 62,000 shares in the prior three months. This is a routine compliance disclosure; it informs liquidity and insider selling activity but contains no operational or financial performance data.

Corporate Governance Specialist

TL;DR: Filing is a standard Rule 144 disclosure showing option exercise followed by planned sale; it documents compliance and insider liquidity.

The notice provides required boilerplate representations about material non-public information and records acquisition details (stock option exercise) and payment method (cash). The schedule of recent sales offers transparency on insider disposition history. From a governance perspective, the filing demonstrates adherence to securities rules and public disclosure obligations but does not indicate any governance breaches or new material events.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Co. Inc. 501 N. Broadway St. Louis MO 63102	20000	1662200.00	105370000	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Stock Option Exercise	Corcept Therapeutics Inc.			20000	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Sean Maduck 101 Redwood Shores Parkway Redwood Ciity CA 94065	Common	07/01/2025	205	15058.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	4315	317054.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/18/2025	473	34747.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/01/2025	35007	2373238.00
Sean Maduck 101 Redwood Shores Parkway Redwood City CA 94065	Common	09/02/2025	20000	1409828.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 filed for CORT disclose?

The filing discloses a proposed sale of 20,000 common shares through Stifel Nicolaus with an aggregate market value of $1,662,200 and an approximate sale date of 10/01/2025.

How were the 20,000 shares acquired according to the filing?

The filing states the shares were acquired by stock option exercise on 10/01/2025 and paid for in cash on that date.

Has this insider sold other CORT shares recently?

Yes. The filer reported selling a total of 62,000 shares over the past three months on dates including 07/01/2025, 07/17/2025, 07/18/2025, 08/01/2025, and 09/02/2025 with listed gross proceeds for each trade.

Through which broker will the proposed sale be executed?

The proposed sale is to be executed through Stifel Nicolaus & Co. Inc. located at 501 N. Broadway, St. Louis, MO.

Does the filing state any undisclosed material information about Corcept?

By signing the notice, the seller represents they do not know any material adverse information about the issuer that has not been publicly disclosed.